Factors affecting overall survival and progression-free survival in patients with metastatic castration resistant prostate cancer received 177Lu PSMA I&T therapy.

Lutetium-177 (177Lu) prostate specific membrane antigen (PSMA) radionuclide therapy (RNT) is an effective and safe treatment option in patients with metastatic castration resistant prostate cancer (mCRPC).